Related Experiment Videos
Renal failure after intravesical mitomycin C
1Veterans Administration Medical Center, Syracuse, New York.
Urology
|October 1, 1989
Abstract:
Severe side effects, local or systemic, are uncommon with intravesically administered mitomycin C. Bladder fibrosis and contracture, with resultant renal failure, are unusual but possible.
Insights
Intravesical mitomycin C rarely causes severe side effects. However, bladder fibrosis, contracture, and subsequent renal failure are uncommon but potential risks.
Area of Science:
- Urology
- Oncology
Background:
- Intravesical chemotherapy is a standard treatment for non-muscle-invasive bladder cancer.
- Mitomycin C is frequently used due to its efficacy and perceived safety profile.
Observation:
- This study reviews the potential for severe local and systemic side effects associated with intravesical mitomycin C administration.
- Specific attention is given to the rare but serious complications affecting the bladder and kidneys.
Findings:
- Severe adverse events, including local and systemic reactions, are infrequent with intravesical mitomycin C.
- Bladder fibrosis and contracture, potentially leading to renal failure, represent unusual but documented complications.
Implications:
- Clinicians should remain vigilant for these rare complications despite the generally favorable safety profile of intravesical mitomycin C.
- Patient counseling should include information on the possibility of these severe, albeit uncommon, adverse outcomes.